Literature DB >> 21470072

Enoxaparin: a pharmacologic and clinical review.

Zafar Iqbal1, Marc Cohen.   

Abstract

INTRODUCTION: Both arterial and venous thromboembolism constitute a significant disease burden worldwide, leading to major use of healthcare resources. As anticoagulants play a pivotal role in the treatment of these disorders, it is vital for healthcare providers to have sufficient knowledge of their biochemical and clinical attributes. AREAS COVERED: Enoxaparin is one of the most commonly used low-molecular-weight heparins in a wide variety of thromboembolic disorders and has several advantages over unfractionated heparin. An analysis of its biophysical profile, with special emphasis on pharmacokinetic and pharmacodynamic properties, is undertaken in this article. In addition, most recent major clinical studies elucidating its role in common thromboembolic conditions are discussed, while keeping the historical perspective at hand. Readers will be able to understand the pharmacologic properties of enoxaparin with their clinical relevance for day-to-day use and critically analyze the amount and weight of scientific evidence behind its use in various disorders. EXPERT OPINION: In summary, enoxaparin has been shown, by a vast amount of scientific data, to be a safe and effective agent in the treatment of a whole spectrum of acute coronary syndromes, with similar efficacy and safety in the prevention and treatment of venous thromboembolism.
© 2011 Informa UK, Ltd

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470072     DOI: 10.1517/14656566.2011.570261

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

1.  Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.

Authors:  Todd W Costantini; Emily Min; Kevin Box; Vy Tran; Robert D Winfield; Dale Fortlage; Jay Doucet; Vishal Bansal; Raul Coimbra
Journal:  J Trauma Acute Care Surg       Date:  2013-01       Impact factor: 3.313

2.  A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection.

Authors:  Jacob E Choby; Andrew J Monteith; Lauren E Himmel; Paris Margaritis; Jana K Shirey-Rice; Andrea Pruijssers; Rebecca N Jerome; Jill Pulley; Eric P Skaar
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

Review 3.  Bioequivalence of a biosimilar enoxaparin (Cloti-Xa™) and its innovator (Clexane® ): A single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced study in healthy human subjects.

Authors:  Sumit Saxena; Manu Chaudhary; Saransh Chaudhary; Anmol Aggarwal
Journal:  Pharmacol Res Perspect       Date:  2022-08

4.  Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers.

Authors:  Javier Martínez González; Mayte Monreal; Ignacio Ayani Almagia; Jordi Llaudó Garín; Lourdes Ochoa Díaz de Monasterioguren; Ibón Gutierro Adúriz
Journal:  Drug Des Devel Ther       Date:  2018-03-19       Impact factor: 4.162

5.  The Role of Jinhuang Powder to Prevent Adverse Effects of Subcutaneous Injection of Enoxaparin Sodium.

Authors:  Meng Zhang; Xiang Zhang; Chunlan Wang; Yangfang Shen; Jianan Fu
Journal:  Emerg Med Int       Date:  2022-08-24       Impact factor: 1.621

Review 6.  Heparin Mimetics: Their Therapeutic Potential.

Authors:  Shifaza Mohamed; Deirdre R Coombe
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.